Claris Lifesciences Limited
Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com , CIN : L85110GJ1994PLC022543
Unaudited Financial Results for the Quarter ended June 30, 2015

(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended			Year to Date	Quarter Ended			Year to Date
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
PART I								
1. Income from Operations								
a. Net Sales/Income from Operations (Net of excise duty)	18,651.48	15,472.80	15,105.13	78,011.30	13,739.44	13,075.43	13,753.56	70,222.16
b. Other Operating Income	542.59	319.28	553.05	1,963.93	576.02	338.08	553.05	2,006.25
Total Income from operations (net)	**19,194.07**	**15,792.08**	**15,658.18**	**79,975.23**	**14,315.46**	**13,413.51**	**14,306.61**	**72,228.41**
2. Expenses								
a. Cost of materials consumed	3,706.22	2,399.68	2,293.57	11,873.05	-	-	2,293.57	7,616.28
b. Purchase of stock-in- trade	4,345.81	4,844.13	4,531.61	26,274.43	12,891.55	12,259.03	4,112.95	37,267.94
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(350.23)	(610.33)	360.59	(2,691.47)	-	-	377.42	(427.69)
d. Employee benefits expense	1,840.84	2,942.30	2,131.95	9,257.02	527.75	1,664.02	1,952.61	6,661.50
e. Depreciation and amortisation expense	1,037.29	891.75	1,031.64	4,904.83	174.97	86.42	843.41	2,957.56
f. Other expenses	4,741.23	3,861.80	3,502.01	19,714.87	890.86	896.09	3,250.63	12,475.07
Total Expenses	**15,321.16**	**14,329.33**	**13,851.37**	**69,332.73**	**14,485.13**	**14,905.56**	**12,830.59**	**66,550.66**
3. Profit / (Loss) from Operations before Other Income, finance costs and exceptional Items (1-2)	**3,872.91**	**1,462.75**	**1,806.81**	**10,642.50**	**(169.67)**	**(1,492.05)**	**1,476.02**	**5,677.75**
4. Other Income	858.36	1,378.38	1,305.14	8,630.35	1,045.36	1,973.61	1,379.69	7,625.52
5. Profit / (Loss) from ordinary activities before finance costs and exceptional Items (3+4)	**4,731.27**	**2,841.13**	**3,111.95**	**19,272.85**	**875.69**	**481.56**	**2,855.71**	**13,303.27**
6. Finance Costs	1,022.72	1,045.89	909.18	4,826.04	42.88	58.49	904.86	3,104.40
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	**3,708.55**	**1,795.24**	**2,202.77**	**14,446.81**	**832.81**	**423.07**	**1,950.85**	**10,198.87**
8. Exceptional Items [Income / (Expense)]	-	-	-	-	-	-	-	523.03
9. Profit / (Loss) from Ordinary Activities before tax (7+8)	**3,708.55**	**1,795.24**	**2,202.77**	**14,446.81**	**832.81**	**423.07**	**1,950.85**	**10,721.90**
10. Tax Expense	1,475.88	545.09	596.08	(1,220.36)	191.03	38.65	590.80	(3,147.06)
11. Net Profit / (Loss) from Ordinary Activities after tax (9-10)	**2,232.67**	**1,250.15**	**1,606.69**	**15,667.17**	**641.78**	**384.42**	**1,360.05**	**13,868.96**
12. Extraordinary Item	-	-	-	-	-	-	-	-
13. Net Profit / (Loss) for the period (11-12)	**2,232.67**	**1,250.15**	**1,606.69**	**15,667.17**	**641.78**	**384.42**	**1,360.05**	**13,868.96**
14. Share in Profit/(Loss) from Associate	(204.03)	(206.02)	(58.90)	(719.18)	-	-	-	-
15. Minority interest	-	-	-	-	-	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	**2,028.64**	**1,044.13**	**1,547.79**	**14,947.99**	**641.78**	**384.42**	**1,360.05**	**13,868.96**
17. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)	**5,456.78**	**5,456.78**	**5,456.78**	**5,456.78**	**5,456.78**	**5,456.78**	**5,456.78**	**5,456.78**
18. Reserve excluding Revaluation Reserves (As per Balance Sheet of previous accounting year)	**-**	**-**	**-**	**126,214.11**	**-**	**-**	**-**	**80,300.36**
19. Basic and Diluted Earnings Per Share (EPS) (before & after extraordinary items) (of Rs. 10/- each) (Not Annualised)	**3.72**	**1.91**	**2.53**	**25.89**	**1.18**	**0.70**	**2.22**	**24.02**
See accompanying note to the financial results								

Claris Lifesciences Limited
Regd. Office: Claris Corporate Headquarters, Nr. Parimal Railway Crossing, Ellisbridge, Ahmedabad – 380006
website : www.clarislifesciences.com, e-mail : investorservices.corp@clarislifesciences.com , CIN : L85110GJ1994PLC022543
Unaudited Financial Results for the Quarter ended June 30, 2015

(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended			Year to Date	Quarter Ended			Year to Date
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
PART II								
A PARTICULARS OF SHAREHOLDING								
1. Public Shareholding								
- Number of shares	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801
- Percentage of shareholding	39.01	39.01	39.01	39.01	39.01	39.01	39.01	39.01
2. Promoters and Promoter group shareholding								
a) Pledged/Encumbered								
- Number of shares	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.81	17.81	17.81	17.81	17.81	17.81	17.81	17.81
- Percentage of shares (as a% of the total share capital of the Company)	10.86	10.86	10.86	10.86	10.86	10.86	10.86	10.86
b) Non-encumbered								
- Number of Shares	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	82.19	82.19	82.19	82.19	82.19	82.19	82.19	82.19
- Percentage of shares (as a % of the total share capital of the Company)	50.13	50.13	50.13	50.13	50.13	50.13	50.13	50.13
B INVESTOR COMPLAINTS								
Pending at the beginning of the quarter	NIL							
Received during the quarter	NIL							
Disposed of during the quarter	NIL							
Remaining unresolved at the end of the quarter	NIL							

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2015

2 Consequent to the applicability of Companies Act , 2013 (The Act) to accounting periods commencing from 1st April 2015 to the Company , the Company has charged depreciation on various fixed assets as per the useful lives specified in part C of Schedule II of the Companies Act 2013. The carrying value,net-off residual value of the fixed assets whose useful lives are already exhausted on 31st March 2015 have been adjusted to retained earnings. Had there not been any change in useful lives of the fixed assets as compared to previous quarter, depreciation for the current quarter would have been lower by Rs. 85.84 lacs.

3 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.

4 During the financial period of fifteen months ended on 31st March,2015 , on receipt of necessary approvals from Board of Directors and Shareholders of the Company at thier meetings held on 4th July, 2014 and 3rd September, 2014 respectively in respect of transfer of its Injectables Business on Slump Sale basis, the Company has transferred its Injectables Business to its wholly owned subsidiary namely Claris Injectables Limited (formerly known as Claris Lifesciences International Limited) on 31st October, 2014. The business transfer involved transfer of relevant assets and liabilities as stated in the Business Transfer Agreement of Injectables Business on a "slump sale basis" for an agreed cash consideration of Rs. 55,400 lacs. The Company has registered a profit of Rs 523.03 lacs on account of slump sale of Injectables Business.

The key financial number pertaining to the discontinued business : **(Rs in Lacs)**

Particulars	Consolidated				Standalone			
	Quarter Ended			Period ended	Quarter Ended			*Period ended
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
Revenue	-	-	-	-	-	-	12,220.88	35,254.24
Expenditure	-	-	-	-	-	-	10,668.76	29,591.40
PBT	-	-	-	-	-	-	1,552.12	5,662.84
PAT	-	-	-	-	-	-	1,105.30	4,010.53
						-		

Particulars	Consolidated period ended	Standalone period ended
	31st Oct 2014	31st Oct 2014
	Unaudited	Unaudited
Total Assets	-	102,163.15
Total Liabilities	-	47,286.18

* The Company Operates in single segment and in the view of the common expenditure - employee,marketing expenses, logistic & distribution arrangements and general corporate overheads are not separately identifiable for the identified products. However , the figures of Profit Before Tax and Profit After Tax for the period 1st January, 2014 to 31st March, 2015 have been apportioned and calculated on best estimated basis. Since the Business has been transferred to wholly owned subsidiary, there is no impact on consolidated financial results of the Company due to transfer of Injectable Business (i.e. Discontinued Operation).

5 In the standalone financial result for the fifteen months period ended on 31st March,2015 (audited) , the exceptional item stated therein of Rs. 523.03 lacs pertains to profit on transfer of Injectables Business to Claris Injectables Limited, the wholly owned subsidiary of the Company, on a slump sale basis as stated in note 4 above.

6 The figures for the previous quarter and year have been regrouped / rearranged,wherever necessary.

For Claris Lifesciences Limited

Place: Ahmedabad
Date: 13th August, 2015

Chandrasingh S Purohit
Whole-time Director & CFO